Travere Therapeutics Inc

NASDAQ:TVTX  
27.58
+0.43 (+1.58%)
Earnings Announcements

Travere Therapeutics Reports Q2 2022 Financial Results

Published: 08/04/2022 11:43 GMT
Travere Therapeutics Inc (TVTX) - Travere Therapeutics Reports Second Quarter 2022 Financial Results.
Total Revenue for Q2 2022 Was $54.2 Million.
Net Loss for Q2 of 2022 $1.05 per Basic Share.
Non-GAAP Adjusted Basis, Net Loss for Q2 of 2022 Was $0.65 per Basic Share.
Q2 Earnings per Share View $-0.88, Revenue View $49.6 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $54.35 Million
Adjusted EPS is expected to be -$0.93

Next Quarter Revenue Guidance is expected to be $64.86 Million
Next Quarter EPS Guidance is expected to be -$0.89

More details on our Analysts Page.